Biomedical Imaging
Extract more from images
to drive Drug Discovery
Ardigen Biomedical Imaging Unit enables the identification of small molecule drug candidates through its AI Technology Platform. The Platform integrates the most recent advancements in AI (computer vision and cheminformatics) with molecular biology and medicinal chemistry, bridging the gap between cell imaging and small molecule design. Our unique approach of combining molecular structures, high content screening (HCS) images, and omics data allows us to obtain reliable predictions of Modes of Action and other molecular properties, identify HCS hits, and predict hit candidates. Moreover, its generative component enables fast library design and accelerates the process of lead optimization.
JUMP-CP SUPPORTING PARTNER
Check our tool to explore JUMP-CP data. JUMP-CP Data Explorer
Ardigen phenAID Platform Capabilities
Combine Varied Data Types Through Artificial Intelligence
Ardigen phenAID Platform at Any Stage of Your Research:
Our solution will improve your drug design process through seamless AI-lab integration. The AI platform is a comprehensive solution that fits into your drug discovery process and can be used out-of-the-box in every step of the process. We can increase your chances of obtaining a drug candidate that will successfully pass the clinical trials. Whether you are just starting your project and looking for compounds to screen, or if you have already gathered phenotypic screening outcomes, we can help.
With our platform you are able to:
- find the targets and off-targets of your molecules;
- narrow the chemical search space;
- optimize your compounds to obtain the desired phenotype;
- assign Mode of Action to chemical compounds.
